Repression of metadherin inhibits biological behavior of prostate cancer cells and enhances their sensitivity to cisplatin
Metadherin (MTDH), also known as astrocyte-elevated gene-1, was first cloned in 2002 and has been confirmed as an oncogene in numerous types of cancer by previous studies. Overexpression of MTDH has been observed in multiple types of cancer, including breast, esophageal, prostate, cervical and non-s...
Main Authors: | WEI, YONG-BAO, GUO, QIONG, GAO, YUN-LIANG, YAN, BIN, WANG, ZHAO, YANG, JIN-RUI, LIU, WEI |
---|---|
Format: | Online |
Language: | English |
Published: |
D.A. Spandidos
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438956/ |
Similar Items
-
Metadherin regulates epithelial–mesenchymal transition in carcinoma
by: Wang, Zhao, et al.
Published: (2016) -
Molecular Modification of Metadherin/MTDH Impacts the Sensitivity of Breast Cancer to Doxorubicin
by: Song, Zhenchuan, et al.
Published: (2015) -
MicroRNA-320a inhibits breast cancer metastasis by targeting metadherin
by: Yu, Juan, et al.
Published: (2016) -
Identification of Novel Variants of Metadherin in Breast Cancer
by: Liu, Xianqiang, et al.
Published: (2011) -
Metadherin Contributes to the Pathogenesis of Diffuse Large B-cell Lymphoma
by: Ge, Xueling, et al.
Published: (2012)